Natera, Inc. $NTRA Shares Acquired by Zweig DiMenna Associates LLC

Zweig DiMenna Associates LLC increased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 3.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 124,100 shares of the medical research company’s stock after buying an additional 3,610 shares during the quarter. Natera comprises approximately 2.0% of Zweig DiMenna Associates LLC’s investment portfolio, making the stock its 13th biggest holding. Zweig DiMenna Associates LLC owned 0.09% of Natera worth $20,965,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Bank of Jackson Hole Trust acquired a new position in Natera during the first quarter valued at $29,000. Hilltop National Bank acquired a new stake in Natera during the second quarter worth about $33,000. Oliver Lagore Vanvalin Investment Group acquired a new stake in Natera during the second quarter worth about $36,000. TCTC Holdings LLC grew its holdings in Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after acquiring an additional 124 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its position in Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after purchasing an additional 106 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Transactions at Natera

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares of the company’s stock, valued at $1,004,444.85. This represents a 31.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 14,083 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $160.00, for a total value of $2,253,280.00. Following the sale, the chief executive officer owned 154,072 shares of the company’s stock, valued at $24,651,520. The trade was a 8.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 61,064 shares of company stock worth $10,477,848 over the last three months. 5.63% of the stock is owned by insiders.

Natera Stock Up 3.0%

Shares of NASDAQ NTRA opened at $198.93 on Friday. The company’s 50-day simple moving average is $174.44 and its 200-day simple moving average is $161.99. Natera, Inc. has a 52-week low of $120.67 and a 52-week high of $199.21. The firm has a market cap of $27.30 billion, a price-to-earnings ratio of -104.15 and a beta of 1.74.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to analysts’ expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several recent research reports. Barclays restated an “overweight” rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the company an “outperform” rating in a report on Tuesday, September 2nd. BTIG Research lifted their price objective on shares of Natera from $200.00 to $210.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $200.00 target price on shares of Natera in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $194.89.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.